# NeuroCriticalAI - Stroke & TBI Platform
## Venture Specification

**Version:** 1.0
**Date:** March 2, 2026
**Status:** GO - Pursue
**Score:** 8.33/10

---

## Executive Summary

NeuroCriticalAI is an AI-powered platform for neurocritical care specialists that automates stroke detection, TBI monitoring, seizure detection, hemorrhage expansion prediction, and neuro-critical care workflow optimization. The platform combines computer vision for CT angiography, time-series ML for EEG/ICP monitoring, and predictive analytics for hemorrhage expansion into a single neuro-critical care suite.

**Key Metrics:**
- Target Market: 5,000+ neurocritical care specialists in the US
- Entry Price: $3,000-$8,000/month per hospital
- Unit Economics: CAC $400, LTV $144,000, Gross Margin 82%
- Validation Threshold: >0.95 sensitivity LVO detection, 50% faster than radiologist

---

## 1. Problem Statement

### 1.1 Core Problems

**Stroke Care Challenges:**
- Stroke is the #5 cause of death in the United States
- "Time is brain" - 1.9 million neurons lost per minute during ischemic stroke
- Large vessel occlusion (LVO) requires mechanical thrombectomy within 6-24 hours
- CT angiogram interpretation delays treatment decisions
- CT perfusion (CTP) analysis requires expertise to distinguish penumbra vs. infarct core

**Traumatic Brain Injury (TBI) Challenges:**
- High mortality rates with severe TBI
- Intracranial pressure (ICP) monitoring is complex and requires constant vigilance
- Secondary brain injury progression difficult to predict
- Multimodal monitoring data overload for clinicians

**Seizure Detection Challenges:**
- Non-convulsive seizures common in neuro-ICU patients
- Continuous EEG monitoring requires expert interpretation
- 24/7 neurophysiology coverage not available at most centers
- Seizure-related secondary injury is time-sensitive

**Hemorrhage Expansion:**
- Intracerebral hemorrhage expansion predicts poor outcomes
- Early prediction enables intervention (blood pressure management, reversal agents)
- Current prediction models require manual calculation
- CT-based ML prediction shows promise but not widely available

### 1.2 Market Pain Points

| Pain Point | Impact | Frequency |
|------------|--------|-----------|
| Delayed LVO diagnosis | Missed thrombectomy window | Daily in stroke centers |
| EEG interpretation gaps | Missed non-convulsive seizures | Continuous |
| ICP crisis prediction failure | Secondary brain injury | Daily in neuro-ICU |
| Hemorrhage expansion surprise | Mortality increase | 30% of ICH cases |
| Radiologist burnout | Diagnostic errors | Systemic |

### 1.3 Economic Impact

- Stroke costs $34 billion annually in the US
- TBI costs $76 billion annually
- Each hour of treatment delay increases stroke disability costs by $5,000+
- Malpractice exposure for delayed diagnosis averages $500K per case

---

## 2. Solution

### 2.1 Platform Overview

NeuroCriticalAI provides an integrated AI suite addressing the full spectrum of neurocritical care:

**Core Modules:**

1. **Stroke Detection AI**
   - CT Angiogram (CTA) analysis for Large Vessel Occlusion detection
   - CT Perfusion (CTP) analysis (penumbra vs. infarct core)
   - ASPECTS score automation
   - Collateral scoring

2. **TBI Monitoring Suite**
   - Intracranial Pressure (ICP) trend analysis
   - ICP crisis prediction (30-minute horizon)
   - Cerebral perfusion pressure optimization
   - Secondary injury risk stratification

3. **EEG Seizure Detection**
   - Real-time seizure detection (convulsive and non-convulsive)
   - Seizure burden quantification
   - Status epilepticus alerting
   - Background pattern analysis (suppression, burst suppression)

4. **Hemorrhage Expansion Prediction**
   - CT-based ML prediction
   - Spot sign detection
   - Expansion probability score
   - Growth trajectory modeling

5. **Workflow Intelligence**
   - Automated report generation (GPT-4)
   - Quality metrics dashboard
   - Stroke center certification support
   - Multidisciplinary communication

### 2.2 Technical Architecture

```
┌─────────────────────────────────────────────────────────────────┐
│                        NEUROCRITICAL AI                          │
├─────────────────────────────────────────────────────────────────┤
│  ┌─────────────┐  ┌─────────────┐  ┌─────────────┐             │
│  │  CTA AI     │  │  CTP AI     │  │  EEG AI     │             │
│  │  (CNN)      │  │  (CNN+ML)   │  │  (LSTM/     │             │
│  │             │  │             │  │   Transformer)│            │
│  └─────────────┘  └─────────────┘  └─────────────┘             │
│  ┌─────────────┐  ┌─────────────┐  ┌─────────────┐             │
│  │  ICP AI     │  │  Expansion  │  │  Reporting  │             │
│  │  (Time-     │  │  Predictor  │  │  (GPT-4)    │             │
│  │   Series)   │  │  (Random    │  │             │             │
│  │             │  │   Forest)   │  │             │             │
│  └─────────────┘  └─────────────┘  └─────────────┘             │
├─────────────────────────────────────────────────────────────────┤
│                    INTEGRATION LAYER                            │
│  PACS  │  EEG Monitors  │  ICU Monitors  │  EHR  │  Mobile     │
└─────────────────────────────────────────────────────────────────┘
```

### 2.3 AI Models

| Model | Input | Output | Accuracy Target |
|-------|-------|--------|-----------------|
| LVO Detection CNN | CTA 3D volume | Occlusion location + confidence | >95% sensitivity, >80% specificity |
| Penumbra Classifier | CTP maps | Core/penumbra volumes | >90% Dice coefficient |
| ICP Predictor | ICP time-series | Crisis probability (30min) | >85% AUC |
| Seizure Detector | EEG channels | Seizure onset + type | >90% sensitivity, <1 false alarm/day |
| Expansion Predictor | Non-contrast CT | Expansion probability | >80% AUC |

### 2.4 Key Differentiators

**vs. RapidAI/Viz.ai:**
- Combined stroke + TBI + EEG platform (competitors are stroke-only)
- ICP monitoring and crisis prediction
- EEG seizure detection
- Hemorrhage expansion prediction

**vs. Radiology AI Platforms:**
- Neuro-critical care specialist focus (not radiology)
- Workflow designed for neuro-ICU
- Real-time monitoring capabilities
- Multimodal data integration

---

## 3. Market Analysis

### 3.1 Target Market

**Primary Customers:**
- Neurointensivists (board-certified: ~1,500 in US)
- Neurocritical care physicians (~2,000 in US)
- Stroke neurologists (~1,500 in US)

**Secondary Customers:**
- Comprehensive Stroke Centers (~500 certified in US)
- Primary Stroke Centers (~1,000 certified in US)
- Neuro-ICUs (~200 major academic centers)
- Emergency Departments with stroke pathways

**Tertiary Customers:**
- Tele-stroke networks
- Critical care hospitals
- VA hospitals

### 3.2 Market Sizing

| Segment | Count | Addressable | Penetration (Year 3) |
|---------|-------|-------------|---------------------|
| Comprehensive Stroke Centers | 500 | 100% | 40% |
| Primary Stroke Centers | 1,000 | 60% | 15% |
| Neuro-ICUs (Academic) | 200 | 100% | 60% |
| Tele-Stroke Networks | 50 | 100% | 50% |

**TAM (Total Addressable Market):**
- 1,750 hospitals
- Average $4,000/month = $84M annual recurring

**SAM (Serviceable Addressable Market):**
- 750 comprehensive stroke centers + academic neuro-ICUs
- $36M annual recurring

**SOM (Serviceable Obtainable Market - Year 3):**
- 180 hospitals at $4,000 ARPU = $8.6M annual recurring

### 3.3 Market Trends

**Driving Forces:**
1. **Aging Population:** 65+ population growing 3x faster than total population
2. **Obesity Epidemic:** Stroke risk factors increasing
3. **Thrombectomy Expansion:** DAWN/DEFUSE-3 trials expanded treatment window to 24 hours
4. **CT Perfusion Availability:** More scanners capable, faster acquisition
5. **EEG Monitoring:** Continuous EEG becoming standard in neuro-ICU
6. **Stroke Center Certification:** Joint Commission requirements drive quality metrics
7. **Value-Based Care:** Outcomes tracking required for reimbursement

**Regulatory Tailwinds:**
- Medicare coverage for mechanical thrombectomy (2019)
- CMS stroke care quality measures (STK-1 to STK-8)
- Get With The Guidelines-Stroke certification requirements

### 3.4 Competitive Landscape

**Direct Competitors - Stroke:**
- **RapidAI:** Stroke detection AI, well-established, ~$50M funding
- **Viz.ai:** Stroke AI platform, well-funded, ~$250M+ funding
- **StrokeViewer:** Netherlands-based, European focus

**Direct Competitors - TBI:**
- **ICURO:** TBI monitoring, some AI capabilities
- **BrainScope:** TBI diagnostic (mild TBI focus)

**Indirect Competitors:**
- **Radiology AI platforms:** Aidoc, Annalise.ai (stroke modules)
- **EHR-embedded tools:** Epic, Cerner (basic stroke pathways)

**Competitive Advantages:**
1. **Integrated Suite:** Only platform combining stroke + TBI + EEG
2. **Neuro-ICU Focus:** Designed for neurocritical care workflow
3. **Real-time Monitoring:** Live ICP/EEG analysis
4. **Predictive Analytics:** Hemorrhage expansion, ICP crisis prediction

---

## 4. Business Model

### 4.1 Pricing Structure

**Per-Hospital Subscription:**

| Tier | Price | Features | Target |
|------|-------|----------|--------|
| Starter | $3,000/month | LVO detection + CTP analysis + ASPECTS | Primary Stroke Centers |
| Professional | $4,000/month | Full stroke suite + TBI monitoring + EEG | Comprehensive Stroke Centers |
| Enterprise | $8,000/month | Multi-hospital + white-label + research integration | Health systems |

**Per-Patient Add-On:**
- $50 per AI-assisted stroke case (beyond included tiers)
- Billed monthly based on utilization

**Implementation Fees:**
- $25,000 one-time (PACS/EHR integration, training)
- Waived for annual contracts

### 4.2 Unit Economics

**Customer Acquisition Cost (CAC):**
- NCS Conference: $15,000 ÷ 50 leads = $300/lead × 20% conversion = $1,500
- International Stroke Conference: $20,000 ÷ 80 leads = $250/lead × 25% conversion = $1,000
- Referrals: $50 (case study reviews)
- Weighted Average: $400

**Lifetime Value (LTV):**
- Average ARPU: $4,000/month
- Gross Margin: 82%
- Monthly Gross Profit: $3,280
- Retention: 36 months (high switching costs)
- LTV: $3,280 × 36 = $118,080

**LTV:CAC Ratio:**
- $118,080 ÷ $400 = 295x

### 4.3 Revenue Projections

**Year 1:**
- 12 hospitals (6 comprehensive + 6 primary)
- Mix: 6 Professional + 6 Starter
- MRR: (6 × $4,000) + (6 × $3,000) = $42,000
- Per-patient add-ons: $8,000/month
- **Total MRR: $50,000**
- **Annual ARR: $600,000**

**Year 2:**
- 60 hospitals (30 comprehensive + 30 primary)
- Mix: 30 Professional + 20 Starter + 10 Enterprise
- MRR: (30 × $4,000) + (20 × $3,000) + (10 × $8,000) = $260,000
- Per-patient add-ons: $40,000/month
- **Total MRR: $300,000**
- **Annual ARR: $3,600,000**

**Year 3:**
- 180 hospitals
- Mix: 80 Professional + 60 Starter + 40 Enterprise
- MRR: (80 × $4,000) + (60 × $3,000) + (40 × $8,000) = $820,000
- Per-patient add-ons: $100,000/month
- **Total MRR: $920,000**
- **Annual ARR: $11,000,000**

### 4.4 Gross Margin Analysis

**Cost Components (per $4,000/month subscription):**
| Cost Item | Monthly | % of Revenue |
|-----------|---------|--------------|
| AWS Compute (GPU instances) | $360 | 9% |
| PACS Integration API | $120 | 3% |
| Support | $150 | 3.75% |
| Account Management | $60 | 1.5% |
| Total COGS | $690 | 17.25% |
| **Gross Margin** | $3,310 | **82.75%** |

---

## 5. Go-to-Market Strategy

### 5.1 Launch Strategy

**Phase 1: Validation (Months 1-3)**
- Partner with 1 comprehensive stroke center
- Retrospective LVO detection study
- Publish case study: "AI detected LVO missed on initial read"

**Phase 2: Early Access (Months 4-6)**
- 5 pilot sites (comprehensive stroke centers)
- Free pilot, convert to paid at 90%
- Collect validation data for FDA submission

**Phase 3: Conference Launch (Months 7-12)**
- International Stroke Conference keynote
- Neurocritical Care Society (NCS) annual meeting
- Target 12 paying customers by year-end

### 5.2 Sales Channels

**Primary Channel: Medical Conferences**
- International Stroke Conference (AHA): 5,000+ attendees
- NCS Annual Meeting: 1,500+ neurointensivists
- Society of Critical Care Medicine (SCCM): Neuro track
- American Academy of Neurology (AAN): Stroke section

**Secondary Channel: Publications**
- Neurocritical care journals (Neurocritical Care, Critical Care)
- Stroke journals (Stroke, Journal of Stroke and Cerebrovascular Diseases)
- Case studies: "AI-enabled stroke detection at [Hospital Name]"

**Tertiary Channel: Partnerships**
- Tele-stroke platforms (hub-and-spoke networks)
- PACS vendors (Ambra, Mach7)
- EEG manufacturers (Natus, Nihon Kohden)

### 5.3 Viral Mechanisms

1. **"Time is Brain" Case Studies:** Publish anonymized cases where AI detected stroke faster than standard care
2. **Stroke Network Effects:** Comprehensive stroke centers influence spoke hospitals
3. **NCS Word-of-Mouth:** Neurointensivists are tight-knit community
4. **Quality Metrics:** Publish stroke center performance improvements
5. **Peer-Reviewed Publications:** Validation studies in major journals

### 5.4 Sales Process

| Stage | Duration | Activities |
|-------|----------|------------|
| Lead Generation | Ongoing | Conferences, publications, referrals |
| Initial Contact | 1 week | Demo, clinical use case discussion |
| Technical Evaluation | 2-4 weeks | PACS integration assessment, data security review |
| Pilot | 4-8 weeks | Free pilot, validation data collection |
| Contract Negotiation | 2-4 weeks | Legal review, implementation planning |
| Implementation | 4-6 weeks | Integration, training, go-live |

**Typical Sales Cycle:** 4-6 months (accelerates with referrals)

---

## 6. MVP Roadmap (8 Weeks)

### Week 1-2: Data Collection & Partnership
- [ ] Partner with 1 comprehensive stroke center
- [ ] IRB approval for retrospective study
- [ ] Collect 500+ CTA datasets with LVO annotations
- [ ] Set up secure data pipeline (HIPAA compliant)
- [ ] Define data annotation protocol

**Deliverables:** Data partnership agreement, 500 labeled CTA datasets

### Week 3-5: LVO Detection AI
- [ ] Build 3D CNN for CTA analysis
- [ ] Train on LVO detection (anterior/posterior circulation)
- [ ] Implement occlusion localization
- [ ] Build confidence scoring system
- [ ] Internal validation

**Deliverables:** LVO detection model with >0.95 sensitivity

### Week 6-7: Pilot Deployment
- [ ] Deploy model to stroke center (read-only)
- [ ] Prospective validation (50 cases)
- [ ] Measure: detection speed vs. radiologist
- [ ] Measure: false positive rate
- [ ] Collect user feedback

**Deliverables:** Prospective validation data, user feedback report

### Week 8: Refinement & Demo
- [ ] Refine model based on pilot feedback
- [ ] Build conference demo (anonymized cases)
- [ ] Prepare case study (if LVO detected)
- [ ] Draft abstract for stroke conference

**Deliverables:** Refined model, conference demo materials, case study

### MVP Validation Metrics

| Metric | Target | Why |
|--------|--------|-----|
| LVO Sensitivity | >0.95 | Cannot miss LVO (safety critical) |
| LVO Specificity | >0.80 | Balance false alarms |
| Detection Speed | <2 minutes | 50%+ faster than radiologist |
| Pilot Commitment | 1 center | Letter of intent for paid pilot |

---

## 7. Technical Architecture

### 7.1 Tech Stack

**Backend:**
- Python 3.11+
- FastAPI (REST API)
- Pydantic (data validation)
- Celery (async tasks)

**AI/ML:**
- PyTorch 2.0+
- MONAI (medical imaging)
- scikit-learn
- OpenAI API (GPT-4 for reports)
- NumPy, Pandas

**Frontend:**
- React/TypeScript
- Recharts (visualization)
- Material-UI
- WebSocket (real-time alerts)

**Infrastructure:**
- AWS (US-East, US-West)
- EC2 GPU instances (p3.2xlarge for inference)
- S3 (DICOM storage)
- RDS PostgreSQL
- ECS/Fargate (container orchestration)
- CloudFront (CDN)

**Security/Compliance:**
- HIPAA compliant architecture
- VPC with private subnets
- Encryption at rest and in transit
- BAA with AWS
- SOC 2 Type II (planned)

### 7.2 Integration Architecture

**PACS Integration:**
- DICOMweb standard
- Ambra API
- Mach7 API
- Custom DICOM receivers

**EEG Integration:**
- Natus Xltek API
- Nihon Kohden BSS
- DICOM waveform import
- HL7 ADT messages

**ICP Integration:**
- ICU monitor vendors (Philips, GE)
- HL7/MDSO protocol
- FHIR Observation resources

**EHR Integration:**
- Epic FHIR API
- Cerner HealtheIntent
- SMART on FHIR apps

### 7.3 Data Flow

```
CT Scanner → PACS → DICOMweb → NeuroCriticalAI → LVO Detection
                                                          ↓
                                                Alert → Dashboard → Mobile

EEG Monitor → DICOM Waveform → NeuroCriticalAI → Seizure Detection
                                                          ↓
                                                Alert → Dashboard → Mobile

ICP Monitor → HL7 → NeuroCriticalAI → Crisis Prediction
                                                          ↓
                                                Alert → Dashboard → Mobile
```

---

## 8. Risk Analysis

### 8.1 Critical Risks

**1. FDA Regulatory Pathway**
- **Risk:** Class II medical device requires 510(k) clearance
- **Timeline:** 6-12 months (with existing predicates)
- **Mitigation:** Use 510(k) pathway, leverage existing predicates (RapidAI, Viz.ai)
- **Cost:** $500K-$1M (legal + clinical studies)

**2. CT Data Quality Variability**
- **Risk:** Different scanners, protocols, contrast timing
- **Mitigation:** Robust training data from multiple vendors, normalization techniques
- **Validation:** Multi-site validation before FDA submission

**3. LVO Detection Accuracy**
- **Risk:** Cannot miss LVO (100% sensitivity ideal)
- **Mitigation:** Conservative threshold, human-in-the-loop, escalation protocols
- **Trade-off:** Accept higher false positives vs. missed LVO

**4. Radiologist Resistance**
- **Risk:** Diagnostic "turf war" - radiologists may oppose
- **Mitigation:** Position as "triage" not "replacement", radiologist as customer
- **Ally:** Neurointensivists want this tool

**5. Sales Cycle Length**
- **Risk:** Hospital sales can take 12-18 months
- **Mitigation:** Start with academic centers (faster decisions), conference leads
- **Alternative:** Free research partnership → case study → paid pilot

### 8.2 Secondary Risks

**6. Competition**
- RapidAI and Viz.ai have head start and funding
- Mitigation: Differentiate with TBI + EEG suite, focus on neuro-ICU not radiology

**7. Data Access**
- Limited labeled CTA datasets available
- Mitigation: Hospital partnerships, synthetic data, federated learning

**8. Interpretability**
- "Black box" AI may be resisted by clinicians
- Mitigation: Heat maps, confidence scores, explanation UI

**9. Liability**
- Malpractice exposure if AI misses diagnosis
- Mitigation: Clear disclaimers, human-in-the-loop, insurance

**10. Reimbursement**
- No CPT code for AI-assisted stroke detection
- Mitigation: Position as quality improvement, bundle with stroke center certification

### 8.3 Risk Mitigation Summary

| Risk | Impact | Likelihood | Mitigation |
|------|--------|------------|------------|
| FDA rejection | Critical | Low | 510(k) pathway, experienced legal counsel |
| Missed LVO | Critical | Medium | Conservative thresholds, human review |
| Radiologist opposition | High | Medium | Ally with neurointensivists |
| Long sales cycle | Medium | High | Academic centers first |
| Competition | High | High | TBI/EEG differentiation |

---

## 9. Success Metrics

### 9.1 Clinical Metrics

| Metric | Target | Timeline |
|--------|--------|----------|
| LVO Sensitivity | >0.95 | MVP |
| LVO Specificity | >0.80 | MVP |
| Detection Speed | <2 minutes | MVP |
| ICP Prediction AUC | >0.85 | 6 months |
| Seizure Detection Sensitivity | >0.90 | 6 months |
| Hemorrhage Expansion AUC | >0.80 | 12 months |

### 9.2 Business Metrics

| Metric | Year 1 | Year 2 | Year 3 |
|--------|--------|--------|--------|
| Hospitals | 12 | 60 | 180 |
| MRR | $50K | $300K | $920K |
| Churn | <5% | <5% | <5% |
| NPS | >50 | >60 | >70 |

### 9.3 Go/No-Go Gates

**Gate 1 (Week 8):**
- [ ] >0.95 LVO sensitivity achieved
- [ ] 1 hospital committed to paid pilot
- [ ] FDA pathway identified
- **Decision:** Proceed to pilot or pivot

**Gate 2 (Month 6):**
- [ ] 5 pilot sites active
- [ ] Prospective validation data >200 cases
- [ ] 3 letters of intent for paid contracts
- **Decision:** Raise seed round or continue bootstrapping

**Gate 3 (Month 12):**
- [ ] 12 paying customers
- [ ] 510(k) submission prepared
- [ ] <$400K CAC
- **Decision:** Series A or refine strategy

---

## 10. Team & Requirements

### 10.1 Founding Team

**Must-Have Roles:**
1. **Technical Co-founder:** ML/CV background, PyTorch expertise
2. **Clinical Co-founder:** Neurointensivist, stroke center experience
3. **Business Co-founder:** Healthcare IT sales, FDA experience

**Advisors Needed:**
- Senior neurointensivist (academic stroke center)
- Neuroradiologist (CT interpretation)
- Epileptologist (EEG expertise)
- FDA regulatory attorney
- Health tech CEO (former exit)

### 10.2 Key Hires (Year 1)

| Role | Timeline | Priority |
|------|----------|----------|
| ML Engineer (Medical Imaging) | Month 2 | Critical |
| Full-Stack Developer | Month 2 | Critical |
| Clinical Research Coordinator | Month 3 | High |
| Regulatory Affairs Specialist | Month 4 | High |
| Customer Success Manager | Month 6 | Medium |

### 10.3 Clinical Partners

**Tier 1 Targets (Comprehensive Stroke Centers):**
- Academic medical centers with neurocritical care fellowships
- High-volume thrombectomy programs (>100/year)
- Research-active neurology departments

**Partnership Structure:**
- Research collaboration agreement
- Free access for validation data
- Co-publication opportunities
- Discounted pricing post-FDA

---

## 11. Funding Requirements

### 11.1 Pre-Seed (Months 0-6): $500K

| Use | Amount |
|-----|--------|
| Founders (3 months) | $150K |
| ML Engineer (6 months) | $100K |
| Developer (6 months) | $80K |
| Clinical Research Coordinator | $40K |
| AWS/Infrastructure | $30K |
| Data Licensing | $50K |
| Legal (FDA prep) | $30K |
| Conference/Travel | $20K |

### 11.2 Seed (Months 7-18): $3M

| Use | Amount |
|-----|--------|
| Team (10 FTEs for 12 months) | $1.5M |
| Clinical Studies (FDA 510k) | $500K |
| Sales/Marketing | $400K |
| Infrastructure | $200K |
| Legal/FDA | $250K |
| Buffer | $150K |

### 11.3 Series A (Months 19-36): $10M

- Scale to 180 hospitals
- Complete TBI/EEG modules
- International expansion (EU, Canada)
- Commercial team ramp

---

## 12. Decision Framework

### 12.1 Go/No-Go Summary: **GO**

**Rationale:**

**Strengths:**
1. **Urgent Clinical Need:** "Time is brain" - every minute matters in stroke care
2. **Clear ROI:** Hospitals save money with faster thrombectomy, better outcomes
3. **High Switching Costs:** Once integrated, very hard to displace
4. **AI-Native Problem:** CT angiography = computer vision, time-series = ML
5. **Multiple Revenue Streams:** Stroke + TBI + EEG in one platform
6. **Regulatory Moat:** FDA clearance creates barriers to entry

**Weaknesses:**
1. **Competitive Market:** RapidAI and Viz.ai exist in stroke space
2. **FDA Required:** 6-12 month timeline, $500K-$1M cost
3. **High Accuracy Bar:** Cannot miss LVO (near-perfect sensitivity needed)
4. **Radiologist Resistance:** Potential turf war

**Why This Scores 8.33:**
- Credential + Regulatory pattern (neurocritical care requires FDA)
- Time-critical diagnosis (seconds matter)
- CT angiogram = computer vision (AI-native)
- 5,000 specialists = good market size
- Multiple modules = expansion revenue

### 12.2 Critical Success Factors

1. **Hire Neurointensivist Co-founder:** Clinical credibility is essential
2. **Partner with Comprehensive Stroke Center:** Data access + validation
3. **Start with LVO Detection:** Highest urgency, clearest ROI
4. **Differentiate via TBI + EEG:** Stroke-only competitors exist
5. **Build Conference Relationships:** NCS and Stroke Conference are key
6. **Conservative AI Thresholds:** Better to false alarm than miss LVO
7. **FDA Strategy from Day 1:** Don't build non-compliant architecture

### 12.3 Red Flags (Watch For)

- Can't access labeled CTA data
- LVO sensitivity stuck below 0.95
- Radiologist department blocks pilot
- FDA pathway unclear
- Competitors win key accounts early

---

## 13. Next Steps

1. **Immediate (This Week):**
   - [ ] Identify comprehensive stroke center targets
   - [ ] Draft partnership agreement
   - [ ] Begin IRB preparation

2. **Month 1:**
   - [ ] Secure first hospital partnership
   - [ ] Set up data pipeline (HIPAA compliant)
   - [ ] Begin data annotation

3. **Month 2-3:**
   - [ ] Train initial LVO detection model
   - [ ] Deploy for retrospective validation
   - [ ] Draft conference abstract

4. **Month 4:**
   - [ ] International Stroke Conference presentation
   - [ ] Begin pilot conversations
   - [ ] Prepare 510(k) pre-submission

---

## Appendix

### A. Clinical Background

**Large Vessel Occlusion (LVO):**
- Occlusion of internal carotid, middle cerebral, anterior cerebral, posterior cerebral, basilar arteries
- Requires mechanical thrombectomy
- Treatment window: 6-24 hours depending on collateral status
- Mortality: 50%+ without treatment

**CT Angiography (CTA):**
- CT with IV contrast during arterial phase
- Visualizes cerebral arteries
- Gold standard for LVO diagnosis
- Acquisition: 1-2 minutes

**CT Perfusion (CTP):**
- Maps cerebral blood flow, blood volume, mean transit time
- Distinguishes penumbra (salvageable) from infarct core (dead)
- Essential for extended window thrombectomy decisions

**Intracranial Pressure (ICP):**
- Normal: <20 mmHg
- Crisis: >25 mmHg sustained
- Treatment: Hyperosmolar therapy, sedation, decompressive craniectomy

**EEG Seizures:**
- Non-convulsive seizures: 10-40% of neuro-ICU patients
- Continuous EEG monitoring required for detection
- Treatment: Antiepileptic drugs

### B. Regulatory Pathway

**FDA Classification:**
- Class II medical device
- Product Code: LXN (Computer-Aided Detection)
- 510(k) Pathway: Predicate devices exist (RapidAI, Viz.ai)

**510(k) Requirements:**
1. Predicate device identification
2. Substantial equivalence demonstration
3. Bench testing (accuracy, robustness)
4. Clinical study (retrospective typically sufficient)
5. Cybersecurity documentation
6. Labeling and instructions for use

**Timeline:**
- Pre-submission meeting: Month 4
- Submission: Month 9
- FDA clearance: Month 15-18

### C. Competitive Analysis

| Company | Focus | Funding | Status |
|---------|-------|---------|--------|
| RapidAI | Stroke | ~$50M | FDA cleared, CE marked |
| Viz.ai | Stroke | ~$250M+ | FDA cleared, multi-modality |
| ICURO | TBI | Unknown | Early stage |
| Aidoc | Radiology AI | ~$100M | Stroke module available |
| Annalise.ai | Radiology AI | ~$60M | Stroke module available |

**Differentiation:** Only NeuroCriticalAI combines stroke + TBI + EEG in single neurocritical care suite.

---

**Document Version:** 1.0
**Last Updated:** March 2, 2026
**Next Review:** Upon FDA 510(k) submission
